姓名：宋洋洋

导师情况：博士生导师

研究领域：RNA解码与靶向治疗 

Email: y_song@tongji.edu.cn

通讯地址：上海市杨浦区四平路1239号，同济大学生命科学与技术学院，邮编200092

个人简介：

同济大学“青年百人计划”研究员，博士生导师，兼任同济大学附属普陀人民医院研究员，入选上海市高层次人才计划引进人才。博士毕业于香港大学医学院，曾任新加坡国立大学高级研究科学家。获得国家科技重大专项、上海市自然科学基金项目以及同济大学“医学+X”交叉研究项目资助。

获奖情况：

2019年，6th NCIS Annual Research Meeting, Oral Presentation Award

2017年，RNA协会年会Travel Award

2016年，RNA协会年会Travel Award

2014年，美国癌症协会杰出临床学者奖

2014年，香港特別行政区政府-外展体验奖

2014年，香港大学李嘉诚医学院Faculty Outstanding Research Output Award

2013年，龙荣教授及朱淑濂女士研究生奖学金

2010年，香港大学-大学奖学金·

研究方向：

本课题组立足RNA解码与靶向治疗，通过多模态AI建模破译RNA结构与编辑的调控机制。我们致力于打造从底层基础科学到智能小核酸药物设计与肿瘤模型验证的闭环研究体系。

1. RNA结构调控机制与多模态AI建模。聚焦RNA动态结构对功能调控的分子机制，结合高通量筛选技术构建RNA与分子互作数据体系，发展融合序列、结构与化学信息的多模态人工智能模型。系统解析RNA结构-分子识别-生物效应之间的传递规律，建立RNA成药性预测与分子设计方法，并在细胞与类器官模型中开展功能验证。

2. RNA靶向药物的智能设计与计算平台。面向siRNA、ASO等小核酸药物设计中的靶点可及性与脱靶问题，构建基于多模态数据的智能设计方法。整合RNA序列、结构及修饰信息，建立活性与特异性联合预测模型，开发从靶点输入到候选分子生成与评价的一体化设计平台，提升核酸药物研发效率与可重复性。

3. RNA编辑选择性调控机制及肿瘤功能研究。围绕RNA编辑酶ADAR的选择性调控机制，重点解析双链RNA结构对编辑效率与位点特异性的决定作用。构建结构驱动的预测模型与功能筛选体系，实现对致病性编辑事件的精准调控，并在结直肠癌模型中系统评估其生物学功能与治疗潜力。

4. ADAR1与线粒体dsRNA介导的肿瘤免疫调控机制。研究ADAR1在调控线粒体来源免疫原性dsRNA稳态中的作用，解析其在肿瘤代谢与免疫信号耦联中的分子机制。结合线粒体功能、氧化还原状态（ROS）及先天免疫通路，阐明RNA编辑调控内源性免疫激活的新机制，并探索其在肿瘤免疫干预中的应用潜力。

本课题组常年招聘博士后及科研助理，也欢迎博士生、硕士生和本科生报考和实习。

代表性论文：

*第一作者, #通讯作者

1. Wang W, Qi C, Lv K, Liu Y, Li D, Li X, Yu J, Liu Y, Zhang L, Song Y#, Luo K# and Du S#. First-principles study on magnetic MXenes for free radical trapping and sensing. Journal of Materials Chemistry C. 2026;d6tc00069j.

2. Liu Y, Liang H, Yu J#, Liu Y, Song Y#, Mouham Y, Zhang L, Shiyu Du S#, A DFT study for α-phase uranium and uranium-zirconium alloys in low concentration: Stability, electronic structure, elastic properties and fission gas diffusion. Journal of Nuclear Materials. 2026; 628,156622.

3. Han J*, SongY*, Xie J, Shen H, Gan WL, Ng L, Ng BYL, Ng VHE, Sui X, Tano V, Tang SJ,Chen L. Modulation of m6A RNA modification by DAP3 in cancer cells. Proceedingsof the National Academy of Sciences of the United States of America. 2024Oct;121(40):e2404509121.

4. Song Y*, An O, Ren X,Chan TH, Tay DJ, Tang SJ, Han J, Hong HQ, Ng VHE, Ke X, Shen H, Pitcheshwar P,Lin SJ, Leong KW, Molias FB, Yang H, Kappei D, Chen L. RNA editing mediates thefunctional switch of COPA in a novelmechanism of hepatocarcinogenesis. Journal of Hepatology. 2021 Jan;74(1):135-147.

5. Song Y#,*, Ke X*,Chen L#. Potential use of RNA-based therapeutics for breast cancer treatment. Current Medicinal Chemistry. 2021;28(25):5110-5136.

6. Qi L*, Song Y*, Chan TH, Lin CH, Yang H, HongHQ, Tay DJT, Lin JS, Maury JJP, Tenen DG, Chen L. An RNA editing/dsRNAbinding-independent gene regulatory mechanism of ADARs and its clinicalimplication in cancer. Nucleic Acids Research. 2017 Oct13;45(18):10436-10451.

7. Song Y*, Chen L, Zeng T,Chan TH, Lian QZ, Chow R, Cai X, Li Y, Li Y, Liu M, Wong N, Yuan YF, Pei D,Guan XY. Loss of ATOH8 Increases StemCell Features of Hepatocellular Carcinoma Cells. Gastroenterology. 2015Oct;149(4):1068-81.e5.

共同作者文章：

1. Gan WL, Ren X, Ng VHE, Song Y, Tano V, Han J, Ng L, An O, Xie J, BLY, Tay DJT, Tang SJ, Shen H, Khare S, Young DY, DasGupta R, Chen L. Hepatocyte-macrophage crosstalk via the PGRN-EGFR axis modulates ADAR1-mediated immunity in the liver. Cell Reports. 2024 Jul 23;43(7):114400.

2. Guo J, Chen S, Onishi Y, Shi Q, Song Y, Mei H, Chen L, Kool ET, Zhu RY. RNA Control via Redox-Responsive Acylation. Angew Chem Int Ed Engl. 2024 May 21;63(21):e202402178.

3. Guo M, Chan HMT, Zhou QL, An O, Li Y, Song Y, Tan ZH, Ng HEV, Peramangalam PS, Tan ZQ, Cao X, Iwanaga E, Matsuoka M, Ooi MG, Jen WY, Koh LP, Chan E, Tan LK, Goh Y, Wang W, Koh BTH, Chan MC, Fullwood MJ, Chng WJ, Osato M, Pulikkan JA, Yang H, Chen L, Tenen DG. Core binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis. Blood. 2023 Jun 22;141(25):3078-3090

4. Han J, An O, Ren X, Song Y, Tang SJ, Shen H, Ke XY, Ng VHE, Tay DJ, Tan HQ, Kappei D, Yang H, Chen L. Multilayered Control of Splicing Regulatory Networks by DAP3 Leads to Widespread Alternative Splicing Changes in Cancer. Nature Communications. 2022 Apr 4;13(1):1793.

5. Shen H, An O n, Ren X, Song Y, Tang SJ, Ke XY, Han J, Tay DJ, Ng VHE, Molias FB, Pitcheshwar P, Leong KW, Tan KK, Yang H, Chen L. ADARs act as potent regulators of circular transcriptome in cancer. Nature Communications. 2022 Mar 21;13(1):1508.

6. Molias FB, Sim A, Leong KW, An O, Song Y, Ng VHE, Lim MWJ, Ying C, Teo JXJ, Göke J, Chen L. Antisense RNAs influence promoter usage of their counterpart sense genes in cancer. Cancer Research. 2021 Dec 1;81(23):5849-5861.

7. Tay DJ, Song Y, Peng B, Toh TB, Hooi L, Kaixin Toh DF, Hong H, Tang SJ, Han J, Gan WL, Man Chan TH, Krishna MS, Patil KM, Maraswami M, Loh TP, Dan YY, Zhou L, Bonney GK, Kah-Hoe Chow P, Chen G, Kai-Hua Chow E, Le MT, Chen L. Targeting RNA Editing of Antizyme Inhibitor 1: a Potential Oligonucleotide-Based Antisense Therapy for Cancer. Molecular Therapy. 2021 Nov 3;29(11):3258-3273.

8. An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha SY, Lee MH, Tay ST, Ong X, Keng ATL, Ng M, Tantoso E, Chen L, Tan P, and Yong WP. 3G Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. Cancer Research. 2021 May 15;81(10):2788-2798.

9. Han J, An O, Hong H, Chan TH, Song Y, Shen H, Tang SJ, Lin JS, Ng VHE, Tay DJ, Molias FB, Pitcheshwar P, Yang H, Chen L. Suppression of Adenosine-to-Inosine (A-to-I) RNA Editome by Death Associated Protein 3 (DAP3) Promotes Cancer Progression. Science Advances, 2020 Jun 17;6(25):eaba5136.

10. Tang SJ, Shen H, An O, Hong HQ, Li J, Song Y, Han J, Tay DJ, Ng VHE, Molias FB, Leong KW, Pitcheshwar P, Yang H, Chen L. Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. Nature Communications. 2020 Feb 7;11(1):799.

11. Hong HQ, An O, Chan TH, Ng VHE, Kwok HS, Lin JS, Qi L, Han J, Tay DJT, SJ, Yang H, Song Y, Molias FB, Tenen DG and Chen L. Bidirectional regulation of adenosine-to-inosine (A-to-I) RNA editing by DEAH box helicase 9 (DHX9) in cancer. Nucleic Acids Research, 2018 Sep 6;46(15):7953-7969.

12. Chan TH, Qamra A, Tan KT, Guo J, Yang H, Qi L, Lin JS, Ng VH, Song Y, Hong H, Tay ST, Liu Y, Lee J, Rha SY, Feng Z, So JB, Bin Tean T, Guan YK, Rozen S, Tenen DG, Tan P, Chen L. ADAR-mediated RNA editing predicts progression and prognosis of Gastric Cancer. Gastroenterology. 2016 Oct;151(4):637-650.e10.

13. Liu M, Chen L, Ma N, Chow R, Li Y, Song Y, Chan THM, Fang S, Yang X, Xi S, Jiang L, Li Y, Zeng T, Li Y, Yuan Y, and Guan XY. CHD1L Promotes Lineage Reversion of Hepatocellular Carcinoma through Opening Chromatin for Key Developmental Transcription Factors. Hepatology 2016 May;63(5):1544-59.

14. Chow RK, Sin ST, Liu M, Li Y, Chan TH, Song Y, Chen L, Kwong DL, Guan XY. AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-kB signaling pathways. Oncotarget. 2016 Oct 18;8(48):83469-83479

15. Liu M, Li Y, Chen L, Chan TH, Song Y, Fu L, Zeng T, Dai YD, Zhu YH, Li Y, Chen J, Yuan YF, Guan XY. Allele-specific imbalance of Oxidative Stress Induced Growth Inhibitor 1 contributes to the progression of hepatocellular carcinoma. Gastroenterology, 2014 Apr;146(4):1084-96.

16. Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, Yuan YF, Tenen DG, Guan XY, Chen L. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut.2013 May;63(5):832-43.

17. Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nature Medicine. 2013 Feb;19(2):209-16.

18. Fan H, Chen L, Zhang F, Quan Y, Su X, Qiu X, Zhao Z, Kong KL, Dong S, Song Y, Chan TH, Guan XY. MTSS1, a novel target of DNA methyltransferase 3B, functions as a tumor suppressor in hepatocellular carcinoma. Oncogene. 2012 May 3;31(18):2298-308. 

专利：

1. 关新元, 宋洋洋, 李炎. 中国发明专利：抑癌基因ATOH8及其编码基因的应用, 专利号: CN2014103736103A. 申请时间2013年12月27日，授权时间2016年2月17日

2. 关新元, 宋洋洋, 李炎. 中国发明专利：抑癌基因ATOH8及其编码基因在制备iPSC中的应用, 专利号: CN105420195A. 申请时间2013年12月27日，授权时间2019年5月21日